NICE breast cancer guidance

Two new guidelines on advanced breast cancer and early and locally advanced breast cancer are among the latest guidance to be published by NICE.

In the guideline on advanced breast cancer NICE makes the following recommendations regarding treatment of the disease:

  • Offer endocrine therapy as first-line treatment for the majority of patients with oestrogen receptor-positive disease.
  • For those patients who are not suitable for anthracycline therapy offer systemic chemotherapy in the following sequence:
    - first-line: single-agent docetaxel
    - second-line: single-agent vinorelbine or capecitabine
    - third-line: single-agent capecitabine or vinorelbine (whichever was not used second-line)
  • For patients receiving treatment with trastuzumab, discontinue treatment with the drug at the time of progression outside the central nervous system.

The guideline also makes recommendations regarding diagnosis and assessment, supportive care and the management of complications.

The guideline on early and locally advanced breast cancer offers advice on some of the tests and treatments that patients should be offered, in particular:

  • Reducing the amount of surgery under the arm
  • Breast reconstruction when breast conservation is not possible
  • Chemotherapy and endocrine treatments
  • Biological treatments

With respect to drug therapy the guideline recommends that:

  • Adjuvant chemotherapy or radiotherapy is started as soon as clinically possible within 31 days of completion of surgery in patients having these treatments
  • Postmenopausal women with oestrogen receptor-positive early invasive breast cancer who are not considered to be at low risk are offered an aromatase inhibitor (anastrozole or letrozole), as their initial adjuvant therapy, or tamoxifen if an aromatase inhibitor is contraindicated or not tolerated.

To read the full guidelines visit the NICE website: Advanced Breast Cancer; Early and Locally Advanced Breast Cancer.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more